ES2124372T3 - Composiciones de liberacion prolongada a base de morfina. - Google Patents

Composiciones de liberacion prolongada a base de morfina.

Info

Publication number
ES2124372T3
ES2124372T3 ES94304144T ES94304144T ES2124372T3 ES 2124372 T3 ES2124372 T3 ES 2124372T3 ES 94304144 T ES94304144 T ES 94304144T ES 94304144 T ES94304144 T ES 94304144T ES 2124372 T3 ES2124372 T3 ES 2124372T3
Authority
ES
Spain
Prior art keywords
morphine
pharmaceutically
continuous release
release
particulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94304144T
Other languages
English (en)
Other versions
ES2124372T5 (es
Inventor
Joanne Heafield
Trevor John Knott
Stewart Thomas Leslie
Sandra Therese A Malkowska
Ronald Brown Miller
Derek Allan Prater
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2124372(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9315467A external-priority patent/GB2281204A/en
Priority claimed from GB9324045A external-priority patent/GB2284760B/en
Priority claimed from GB9403922A external-priority patent/GB2288117A/en
Priority claimed from GB9404928A external-priority patent/GB2287880A/en
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of ES2124372T3 publication Critical patent/ES2124372T3/es
Publication of ES2124372T5 publication Critical patent/ES2124372T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

PARA PROVEER UNA FORMULA FARMACEUTICA DE LIBERACION CONTINUADA CONTENIENDO MORFINA QUE ES APROPIADA PARA LA ADMINISTRACION DIARIA DE UNA SOLA VEZ EN UNA BASE, EN UN PRIMER ASPECTO, UNA FORMA DE UNIDAD DE DOSIFICACION DE LIBERACION CONTINUADA ADMINISTRABLE ORALMENTE CONTIENE MORFINA, O UNA SAL DE ELLO ACEPTABLE FARMACEUTICAMENTE, COMO INGREDIENTE ACTIVO, CUYA FORMA DA UN PICO DE NIVEL DE PLASMA DE 1.0 A 6.0 HORAS DESPUES DE LA ADMINISTRACION. EN UN SEGUNDO ASPECTO, LA FORMULA CONTIENE UNA CANTIDAD EFECTIVA DE MORFINA O UNA SAL DE ELLO ACEPTABLE FARMACEUTICAMENTE, CARACTERIZADO POR UN W50 PARA EL METABOLITO M-6-G O PARA LA MORFINA DE ENTRE 4 Y 12 HORAS. EN UN TERCER ASPECTO, LA FORMA UNIDAD DE DOSIFICACION FARMACEUTICA ES OBTENIBLE POR COMPRIMIR LAS MULTIPARTICULADOS QUE COMPRENDEN UNA SUSTANCIA ACTIVA FARMACEUTICAMENTE EN UNA MATRIZ DE MATERIAL FUNDIBLE HIDROFOBICO QUE TIENE UN PUNTO DE FUSION DESDE 35 A 150 C, LA FORMA DE DOSIFICACION OPCIONALMENTE CONTENIENDO EXCIPIENTES DE TABLETADO CONVENCIONAL. EN OTRO ASPECTO DE LA INVENCION, LOS MICROPARTICULADOS DE LIBERACION CONTINUADA QUE CONTIENEN MORFINA O UNA SAL DE ELLO ACEPTABLE FARMACEUTICAMENTE SON FABRICADOS MECANICAMENTE EN UN MEZCLADOR DE ALTA VELOCIDAD UNA MEZCLA DE MORFINA PARTICULADA O UNA SAL DE ELLO ACEPTABLE FARMACEUTICAMENTE Y UN PORTADOR O DILUYENTE FUNDIBLE HIDROFOBICO, PARTICULADO QUE TIENE UN PUNTO DE FUSION DESDE 35 A 150 C Y OPCIONALMENTE UN COMPONENTE DE CONTROL DE LIBERACION QUE COMPRENDE UN MATERIAL FUNDIBLE SOLUBLE EN AGUA O UN MATERIAL SOLUBLE O INSOLUBLE ORGANICO O INORGANICO PARTICULADO A UNA ENTRADA DE VELOCIDAD Y ENERGIA QUE PERMITE AL PORTADOR O DILUYENTE FUNDIR O ABLANDAR POR LO CUAL AGLOMERA, Y ROMPE LOS AGLOMERADOS PARA DAR PARTICULAS DE LIBERACION CONTROLADA.
ES94304144T 1993-07-01 1994-06-09 Composiciones de liberacion sostenida que contienen morfina. Expired - Lifetime ES2124372T5 (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US8624893A 1993-07-01 1993-07-01
US86248 1993-07-01
GB9315467 1993-07-27
GB9315467A GB2281204A (en) 1993-07-27 1993-07-27 Sustained release morphine compositions
US13350393A 1993-10-07 1993-10-07
US133503 1993-10-07
GB9324045A GB2284760B (en) 1993-11-23 1993-11-23 A method of preparing pharmaceutical compositions by melt pelletisation
GB9324045 1993-11-23
GB9403922 1994-03-01
GB9403922A GB2288117A (en) 1994-03-01 1994-03-01 Sustained release morphine
GB9404928 1994-03-14
GB9404928A GB2287880A (en) 1994-03-14 1994-03-14 Production of sustained release compositions

Publications (2)

Publication Number Publication Date
ES2124372T3 true ES2124372T3 (es) 1999-02-01
ES2124372T5 ES2124372T5 (es) 2004-07-16

Family

ID=27547204

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94304144T Expired - Lifetime ES2124372T5 (es) 1993-07-01 1994-06-09 Composiciones de liberacion sostenida que contienen morfina.

Country Status (17)

Country Link
EP (1) EP0636370B2 (es)
JP (1) JP3647897B2 (es)
KR (1) KR100365572B1 (es)
AT (1) ATE172376T1 (es)
AU (2) AU6610594A (es)
CA (1) CA2127166C (es)
CZ (1) CZ287918B6 (es)
DE (1) DE69414046T3 (es)
DK (1) DK0636370T4 (es)
ES (1) ES2124372T5 (es)
FI (1) FI114285B (es)
HU (1) HU220075B (es)
IL (1) IL109944A (es)
NO (1) NO306449B1 (es)
PL (1) PL179282B1 (es)
SG (1) SG50706A1 (es)
SK (1) SK280534B6 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912763B2 (en) 2010-08-04 2021-02-09 Grünenthal GmbH Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
AU735113C (en) * 1991-12-24 2007-06-14 Mundipharma Medical Gmbh Opioid formulations for treating pain
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
TR200001942T2 (tr) * 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
JP5189242B2 (ja) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ES2620293T3 (es) 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
SI1931346T1 (sl) 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
CA2739465C (en) 2008-10-03 2017-01-31 Dr. Falk Pharma Gmbh Compositions and methods for the treatment of bowel diseases with granulated mesalamine
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
DE102016014603A1 (de) 2016-06-30 2018-01-04 Thomas Herkenroth Synthetisches Ayahuasca
KR102316588B1 (ko) * 2021-06-24 2021-10-21 이채훈 화장료 조성물의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
ES2058111T3 (es) † 1986-06-10 1994-11-01 Euro Celtique Sa Composicion de liberacion controlada de dihidrocodeina.
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) † 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
WO1992001446A1 (en) * 1990-07-20 1992-02-06 Aps Research Limited Sustained-release formulations
SE9003296L (sv) † 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
SE9202250D0 (sv) † 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
SE9301057L (sv) † 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912763B2 (en) 2010-08-04 2021-02-09 Grünenthal GmbH Pharmaceutical dosage forms comprising 6′-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine

Also Published As

Publication number Publication date
NO942470L (no) 1995-01-02
AU722358B2 (en) 2000-07-27
AU6610594A (en) 1995-01-12
DE69414046T2 (de) 1999-04-22
CZ155094A3 (en) 1995-01-18
ES2124372T5 (es) 2004-07-16
EP0636370A1 (en) 1995-02-01
EP0636370B1 (en) 1998-10-21
FI943141A0 (fi) 1994-06-30
KR100365572B1 (ko) 2003-07-02
FI943141A7 (fi) 1995-01-02
JP3647897B2 (ja) 2005-05-18
DE69414046T3 (de) 2004-08-26
HU9402007D0 (en) 1994-09-28
IL109944A0 (en) 1994-10-07
JPH07149648A (ja) 1995-06-13
DK0636370T4 (da) 2004-04-19
CZ287918B6 (cs) 2001-03-14
HU220075B (hu) 2001-10-28
PL179282B1 (pl) 2000-08-31
NO942470D0 (no) 1994-06-30
DE69414046D1 (de) 1998-11-26
SK280534B6 (sk) 2000-03-13
KR950002762A (ko) 1995-02-16
AU5299598A (en) 1998-03-26
PL304062A1 (en) 1995-01-09
HUT70938A (en) 1995-11-28
CA2127166C (en) 2006-03-14
IL109944A (en) 1998-12-06
NO306449B1 (no) 1999-11-08
SG50706A1 (en) 1998-07-20
DK0636370T3 (da) 1999-06-28
SK76394A3 (en) 1995-08-09
ATE172376T1 (de) 1998-11-15
CA2127166A1 (en) 1995-01-02
EP0636370B2 (en) 2004-01-02
FI114285B (fi) 2004-09-30

Similar Documents

Publication Publication Date Title
ES2314200T3 (es) Una combinacion de un antagonista de nmda e inhibidores de esterasa de acetilcolina par ael tratamiento de la enfermedad de alzheimer.
DE69414046D1 (de) Morphinenthaltende Arzneizusammensetzungen mit verzögerter Wirkstoffabgabe
BR0012869A (pt) Forma de dosagem farmacêutica de componentes múltiplos
BR0007974A (pt) Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
AR002266A1 (es) Composicion farmaceutica de gelatina blanda o forma de dosis que la incluye
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
PA8594801A1 (es) Formulaciones farmaceuticas liquidas de palanosetron
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
PE20001058A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
PE20091184A1 (es) Formas de dosificacion farmaceutica
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
BR0206627A (pt) Formulação farmacêutica
AR010758A1 (es) Composicion de ibuprofeno que comprende uno o mas medicamentos, preparacion acuosa de dosis unitaria, proceso para preparar dicha preparacion acuosa,proceso para preparar dicha composicion de ibuprofeno, y uso de dicha preparacion
ES2110212T3 (es) Composicion farmaceutica efervescente que contiene ibuprofeno y su procedimiento de preparacion.
AR076864A1 (es) Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
AR053845A1 (es) 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
ATE553750T1 (de) Feste orale mikropartikelförmige darreichungsform zum schutz vor missbrauch
BRPI0411344A (pt) composições farmacêuticas granuladas de atorvastatina, forma de dosagem unitária, método para preparar as mesmas, uso e kit
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
BRPI0512756A (pt) composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
CA2270955A1 (en) Pharmaceutical composition containing morphinan derivative for treating drug dependence
AR044660A1 (es) Composiciones farmaceuticas de atorvastatina
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 636370

Country of ref document: ES